FLNA
Filana TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Composite grade F from latest DB weights. Momentum 0.0 / Value 57.9
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.5.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
0
Value
58
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $6.50
Why
Momentum0 · Δ7d -
Value58 · Δ7d -0.5
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
0
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
60% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-1.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 0.0 / Value 57.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$51.21M
Beta
-0.64
Shares Out
48.31M
P/E (TTM) · Derived
-0.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.69
Rev YoY
-
EPS YoY
-55.9%
Gross Margin
-
Op Margin
-
Net Debt
-$95.5M
Current Ratio
2.19
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology